300759PharmaronSZSE

Pharmaron Beijing Co., Ltd.

康龙化成

300759

Shenzhen Stock Exchange

BoardChiNext of Shenzhen Stock Exchange
IndustryResearch and Experimental Development
ISINCNE100003JW4
ListedJanuary 28, 2019
Websitewww.pharmaron.cn
IR Emailpharmaron@pharmaron.com
Phone(+86)10-57330087
Address8F, Block 1, No.6, Taihe Road, Beijing Economic and Technological Developmenmt Zone, Beijing

Company Profile

The Company provides customers with fully-integrated services covering drug research, development and manufacturing services for innovative pharmaceutical products throughout the research and development cycle. With this end-to-end and fully-integrated business model, we gain significant competitive advantages in deepening customer collaboration, establishing core technical expertise and professional team building which enable us to better support our customers’ innovative R&D programs. 1. Leading fully-integrated pharmaceutical R&D services platform with strong capabilities and comprehensive service offerings across the globe. 2. Global operations, profound experience in pharmaceutical R&D and state-of-the art technologies to provide customized solutions. 3. Committed to utilizing innovative technologies to meet evolving R&D needs and increase efficiency. 4. Dedicated, stable and visionary management teams, experienced talent pools with progressive corporate culture. 5. Reputable, loyal and expanding customer base that contributes to our sustainable growth and business collaboration.

Full description

The Company is a leading fully-integrated pharmaceutical R&D services platform with global operations to accelerate drug innovation for our customers, providing fullyintegrated drug research, development and manufacturing services throughout the research and development cycle. The Company has 21 R&D centers and manufacturing facilities across China, the U.K. and the U.S., and is steadfast in implementing its core strategy of developing an end-to-end, fully integrated and multiple modalitiescapable services platform with global footprints to further support its customers in improving the efficiency and flexibility of their pharmaceutical R&D and manufacturing needs. The Company has built a fully-integrated service platform for small molecule drugs, biologics and CGT products. Meanwhile, the Company is rapidly expanding in new modalities and is committed to becoming a global leader in pharmaceutical R&D services across multiple therapeutic modalities. In addition, the Company will further develop the global footprints of its service platform to provide customers with interdisciplinary and global service solutions, making full use of the Company’s global scientific research talent network and meet customers’ regional strategic needs.

Announcements

0 total
No announcements match your search.